Search hospitals > Florida > Clearwater
Clinical Research of West Florida, Inc.
Claim this profileClearwater, Florida 33765
Global Leader in Systemic Lupus Erythematosus
Global Leader in Crohn's Disease
Conducts research for Lupus
Conducts research for Arthritis
Conducts research for Chronic Obstructive Pulmonary Disease
155 reported clinical trials
5 medical researchers
Summary
Clinical Research of West Florida, Inc. is a medical facility located in Clearwater, Florida. This center is recognized for care of Systemic Lupus Erythematosus, Crohn's Disease, Lupus, Arthritis, Chronic Obstructive Pulmonary Disease and other specialties. Clinical Research of West Florida, Inc. is involved with conducting 155 clinical trials across 81 conditions. There are 5 research doctors associated with this hospital, such as Robert Levin, MD, Leonard Dunn, Leonard Jay Dunn, and Robert William Levin.Area of expertise
1Systemic Lupus Erythematosus
Global Leaderanti-dsDNA positive
ANA positive
anti-Sm positive
2Crohn's Disease
Global LeaderTop PIs
Robert Levin, MDClinical Research of West Florida, Inc. (Clearwater)3 years of reported clinical research
Studies Arthritis
Studies Lupus
20 reported clinical trials
28 drugs studied
Leonard DunnClinical Research of West Florida, Inc. (Clearwater)3 years of reported clinical research
Studies Chronic Obstructive Pulmonary Disease
Studies Obstructive Lung Diseases
7 reported clinical trials
7 drugs studied
Leonard Jay DunnClinical Research of West Florida, Inc. (Clearwater)3 years of reported clinical research
Studies Diabetes
Studies Type 2 Diabetes
6 reported clinical trials
10 drugs studied
Robert William LevinClinical Research of West Florida, Inc. (Clearwater)1 year of reported clinical research
Studies Lupus
Studies Systemic Lupus Erythematosus
2 reported clinical trials
3 drugs studied
Clinical Trials running at Clinical Research of West Florida, Inc.
Systemic Lupus Erythematosus
Lupus
Rheumatoid Arthritis
Arthritis
Crohn's Disease
Obesity
Gout
Type 2 Diabetes
Sjögren's Syndrome
Syndrome
Ianalumab
for Lupus
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Recruiting1 award Phase 31 criteria
Deucravacitinib
for Lupus
This trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Recruiting1 award Phase 3
Litifilimab
for Lupus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: - How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), and the Patient Global Assessment - Visual Analog Scale (PGA-VAS). Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.
Recruiting1 award Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Clinical Research of West Florida, Inc.?
Clinical Research of West Florida, Inc. is a medical facility located in Clearwater, Florida. This center is recognized for care of Systemic Lupus Erythematosus, Crohn's Disease, Lupus, Arthritis, Chronic Obstructive Pulmonary Disease and other specialties. Clinical Research of West Florida, Inc. is involved with conducting 155 clinical trials across 81 conditions. There are 5 research doctors associated with this hospital, such as Robert Levin, MD, Leonard Dunn, Leonard Jay Dunn, and Robert William Levin.